| ID | 1349 |
| Name of the vaccine | GEN-004 |
| Microbe | Bacteria |
| Disease name | Pneumococcal |
| Name of bacteria | Streptococcus pneumoniae |
| Type of vaccine | Subunit |
| Nucleic acid content | DNA |
| Age | 18 to 55 years |
| Description of the vaccine | Pneumococcal recombinant protein subunit vaccine consisting of 3 recombinant T cell antigens. |
| Name of the manufacturer | Genocea Biosciences, Inc. |
| Name of the manufacturing country | United Kingdom |
| Year of manufacture | 2016 |
| Clinical Phase status | Clinical - Phase 2 |
| Bacterial strain | Gram-positive, facultative anaerobic bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Three doses at 4 week intervals. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | Aluminium hydroxide |
| Repurposing | For Pneumonia. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT02116998 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|